CoChat

Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs

Open access
Lund, S H, Aspelund, T, Kirby, P, Russell, G, Einarsson, S, Palsson, O, Stefánsson, E · 2016 · British Journal of Ophthalmology

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To validate a mathematical algorithm that calculates risk of diabetic retinopathy progression in a diabetic population with UK staging (R0-3; M1) of diabetic retinopathy. To establish the utility of the algorithm to reduce screening frequency in this cohort, while maintaining safety standards. RESEARCH DESIGN AND METHODS: The cohort of 9690 diabetic individuals in England, followed for 2 years. The algorithms calculated individual risk for development of preproliferative retinopathy (R2), active proliferative retinopathy (R3A) and diabetic maculopathy (M1) based on clinical data. Screening intervals were determined such that the increase in risk of developing certain stages of retinopathy between screenings was the same for all patients and identical to mean risk in fixed annual screening. Receiver operating characteristic curves were drawn and area under the curve calculated to estimate the prediction capability. RESULTS: The algorithm predicts the occurrence of the given diabetic retinopathy stages with area under the curve =80% for patients with type II diabetes (CI 0.78 to 0.81). Of the cohort 64% is at less than 5% risk of progression to R2, R3A or M1 within 2 years. By applying a 2 year ceiling to the screening interval, patients with type II diabetes are screened on average every 20 months, which is a 40% reduction in frequency compared with annual screening. CONCLUSIONS: The algorithm reliably identifies patients at high risk of developing advanced stages of diabetic retinopathy, including preproliferative R2, active proliferative R3A and maculopathy M1. Majority of patients have less than 5% risk of progression between stages within a year and a small high-risk group is identified. Screening visit frequency and presumably costs in a diabetic retinopathy screening system can be reduced by 40% by using a 2 year ceiling. Individualised risk assessment with 2 year ceiling on screening intervals may be a pragmatic next step in diabetic retinopathy screening in UK, in that safety is maximised and cost reduced by about 40%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2015-307341

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) ROC (receiver operating characteristic) curves for predicting R2 (preproliferative retinopathy), R3A (active proliferative retinopathy) or M1 (diabetic maculopathy), based on the risk estimates of the algorithm. Patients with type I and type II diabetes together. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC (area under curve) was: R2: 0.81 (CI 0.79 to 0.83), R3A: 0.78 (CI 0.75 to 0.81), M1: 0.79 (CI 0.77 to 0.80). (B) ROC curves for predicting R2, R3A or M1, based on the risk estimates of the algorithm. Patients with type I diabetes only. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.72 (CI 0.69 to 0.76), R3A: 0.74 (CI 0.69 to 0.79), M1: 0.68 (CI 0.64 to 0.71). (C) ROC curves for risk predicting of R2, R3A or M1 based on the risk estimates of the algorithm. Patients with type II diabetes only. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.83 (CI 0.81 to 0.84), R3A: 0.80 (CI 0.76 to 0.83), M1: 0.79 (CI 0.78 to 0.81). (D) ROC curves for predicting any of R2, R3A or M1 based on the risk estimates of the algorithm. Coloured in blue are patients with type II diabetes, and patients with type I diabetes are shown in red. The AUC is 70% for patients with type I diabetes (CI 0.67 to 0.73) and 80% for patients with type II diabetes (CI 0.78 to 0.81).
Figure 1 (A) ROC (receiver operating characteristic) curves for predicting R2 (preproliferative retinopathy), R3A (active proliferative retinopathy) or M1 (diabetic maculopathy), based on the risk estimates of the algorithm. Patients with type I and type II diabetes together. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC (area under curve) was: R2: 0.81 (CI 0.79 to 0.83), R3A: 0.78 (CI 0.75 to 0.81), M1: 0.79 (CI 0.77 to 0.80). (B) ROC curves for predicting R2, R3A or M1, based on the risk estimates of the algorithm. Patients with type I diabetes only. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.72 (CI 0.69 to 0.76), R3A: 0.74 (CI 0.69 to 0.79), M1: 0.68 (CI 0.64 to 0.71). (C) ROC curves for risk predicting of R2, R3A or M1 based on the risk estimates of the algorithm. Patients with type II diabetes only. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.83 (CI 0.81 to 0.84), R3A: 0.80 (CI 0.76 to 0.83), M1: 0.79 (CI 0.78 to 0.81). (D) ROC curves for predicting any of R2, R3A or M1 based on the risk estimates of the algorithm. Coloured in blue are patients with type II diabetes, and patients with type I diabetes are shown in red. The AUC is 70% for patients with type I diabetes (CI 0.67 to 0.73) and 80% for patients with type II diabetes (CI 0.78 to 0.81).CC BY-NC · PubMed Central
Figure 2 (A) Distribution of the estimated adjusted risk of developing R2 (preproliferative retinopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years, 8286 had 0–5% risk, 747 had 5–10% and 654 had 10–30% risk of developing R2. (B) Distribution of the estimated adjusted risk of developing R3A (proliferative diabetic retinopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years, 9150 had 0–5% risk, 258 had 5–10% and 279 had 10–30% risk of developing R3A. (C) Distribution of the estimated adjusted risk of developing M1 (diabetic macular oedema) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years 6728 had 0–5% risk, 1506 had 5–10% and 1453 had 10–30% risk of developing M1. (D) Distribution of the estimated adjusted risk of developing any of R2 (moderate or severe preproliferative retinopathy), R3A (proliferative retinopathy) or M1 (diabetic maculopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years 6207 had 0–5% risk, 1666 had 5–10% and 1814 had 10–30% risk of developing R2, R3A or M1.
Figure 2 (A) Distribution of the estimated adjusted risk of developing R2 (preproliferative retinopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years, 8286 had 0–5% risk, 747 had 5–10% and 654 had 10–30% risk of developing R2. (B) Distribution of the estimated adjusted risk of developing R3A (proliferative diabetic retinopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years, 9150 had 0–5% risk, 258 had 5–10% and 279 had 10–30% risk of developing R3A. (C) Distribution of the estimated adjusted risk of developing M1 (diabetic macular oedema) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years 6728 had 0–5% risk, 1506 had 5–10% and 1453 had 10–30% risk of developing M1. (D) Distribution of the estimated adjusted risk of developing any of R2 (moderate or severe preproliferative retinopathy), R3A (proliferative retinopathy) or M1 (diabetic maculopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years 6207 had 0–5% risk, 1666 had 5–10% and 1814 had 10–30% risk of developing R2, R3A or M1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 87

Metadata

Authors
Lund, S. H., Aspelund, T., Kirby, P., Russell, G., Einarsson, S., Palsson, O., & Stefánsson, E.
Affiliations
University of Iceland (IS)
Corresponding author
Stefánsson, E
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2015-09-16
Volume
100
Issue
5
Pages
683-687
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W2264654258
Cited by
84
References
12
Citations by year
2026: 5 · 2025: 3 · 2024: 11 · 2023: 10 · 2022: 13 · 2021: 9 · 2020: 13 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 4
FWCI
4.48
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • British Journal of Ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Hirsla (Landspítali University Hospital) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetic retinopathy, risk prediction algorithm, type 2 diabetes, proliferative diabetic retinopathy, diabetic maculopathy, retinopathy progression, healthcare cost reduction, screening safety
MeSH terms
Algorithms, Diabetes Mellitus, Type 2, Diabetic Retinopathy, England, False Positive Reactions, Female, Humans, Male, Mass Screening, Mathematics, Predictive Value of Tests, ROC Curve, Time Factors, Health Care Costs, Disease Progression, Risk Assessment, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. https://app.cochat.ai/papers/10.1136/bjophthalmol-2015-307341
The paper
Lund, S. H., Aspelund, T., Kirby, P., Russell, G., Einarsson, S., Palsson, O., & Stefánsson, E. (2016). Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2015-307341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.